TITLE

NEWS FOCUS

PUB. DATE
January 2011
SOURCE
Pharmaceutical Representative;Jan2011, Vol. 41 Issue 1, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. Novartis AG lays off 1,400 sales employees as part of the company's restructuring and downsizing. Avila Therapeutics and Sanofi-Aventis forms alliance to discover covalent drugs for treatment of cancer. GlaxoSmithKline acquires China-based pharmaceutical company Nanjing MeiRui Pharma to promote the company's expansion in China.
ACCESSION #
57458352

 

Related Articles

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p3 

    The article reports global developments related to pharmaceutical industry. Novartis AG has joined forces with Schering AG for the commercialization of a novel cancer drug in Europe. GlaxoSmithKline PLC was criticized by the U.S. Food and Drug Administration for providing inaccurate information...

  • Only Fools Rush In. Wirz, Severin // Pharmaceutical Executive;Aug2014, Vol. 34 Issue 8, p44 

    The article reports on increasing mergers and acquisitions in the U.S. pharmaceutical industry citing references to several companies such as medical device group Stryker with Smith & Nephew, GlaxoSmithKline with Novartis, and Medtronic with Covidien and discusses the significance of...

  • CORPORATE.  // MondayMorning;11/9/2009, Vol. 17 Issue 43, p2 

    The article presents news briefs on the U.S. pharmaceutical industry in 2009. Tenet Healthcare Corp. has posted a quarterly net loss of 3 million dollars in 2009's third quarter. Novartis AG will invest 1.25 billion dollars in its research centers in China over the next five years. Johnson &...

  • Company Profiles.  // U.S. Pharma & Healthcare Report;Q2 2009, p71 

    The article presents information about several companies in the pharmaceutical industry in the U.S. Some of them are Pfizer, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) and Novartis. Also discussed are SWOT analysis for the companies, their product portfolio, main competitors and financial...

  • NEOPLASMS.  // MPR - Obstetrician & Gynecologist Edition;2009, p121 

    The article offers information on several drugs for the treatment of neoplasms including evista from Lilly & Co. Ltd., femara from Novartis, and tykerb from glaxosmithkline. It highlights the indications, contraindications, precautions, and adverse reactions of the drugs. It notes that dosing of...

  • Cancer News Round-up.  // PharmaWatch: Cancer;Aug2010, Vol. 9 Issue 8, p2 

    The article offers news briefs related to development of antineoplastic agents. Novartis AG has earned an approval from the U.S. Food and Drug Administration (FDA) for its leukemia drug. Merck Serono SA has resumed its Phase III lung cancer vaccine program. GlaxoSmithKline has received the...

  • PRODUCT UPDATE. Burger, Valerie // Oncology Nursing Forum;Mar2007, Vol. 34 Issue 2, p437 

    The article presents an update on anticancer agents in the U.S. as of March 2007. GlaxoSmithKline has received a priority review from the Food and Drug Administration (FDA) for its Tykerb, a lapatinib ditosylate, due to the drug's potential to treat solid tumor cancers. FDA has granted a...

  • Novartis and GSK Shift M&A Paradigm with Trio of Deals. Cartwright, Heather // PharmaDeals Review;2014, Vol. 2014 Issue 5, p21 

    In a series of paradigm-changing deals that will significantly reshape the companies' businesses, Novartis and GlaxoSmithKline (GSK) have agreed to swap certain assets and combine their consumer healthcare units in order to focus on those business areas in which they are most competitive. While...

  • Panobinostat: A surprising approval for the treatment of multiple myeloma. JALLOH, MOHAMED // Pharmacy Today;Apr2015, Vol. 21 Issue 4, p38 

    The article evaluates an anti-cancer drug panobinostat having brand name Farydak from Novartis AG.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics